Ethyl 2-amino-5-[[1-[(2-ethoxy-2-oxoethyl)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ethyl 2-amino-5-[[1-[(2-ethoxy-2-oxoethyl)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoate
• 化学式: C₁₄H₂₅N₃O₆S
• 分子量: 363.43
• InChiKey: IYXATRBAHYMOQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  24
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  138
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• [EN] METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DES TROUBLES SENSIBLES À LA CYSTÉAMINE
  申请人：THIOGENESIS THERAPEUTICS INC

  公开号：WO2019060634A1

  公开（公告）日：2019-03-28

  The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.

  这项发明涉及治疗囊性氨基酸病和其他对半胱氨酸敏感的疾病的方法，包括在体内给予可转化为半胱氨酸的二硫化物。该方法可以包括向受试者单独给予还原剂，以增加半胱氨酸在给予二硫化物后产生的生物利用度，并延长血浆药代动力学特性。该方法允许受试者体内维持持续的半胱氨酸血浆浓度。
• ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE
  申请人：Yu J. Ruey

  公开号：US20060251597A1

  公开（公告）日：2006-11-09

  This application discloses a composition comprising a malodor compound and an anti-odor ingredient effective for reducing the presence or production of malodor. The composition may be topically applied to a subject and is useful for cosmetic conditions, pharmaceutical indications, or other objectives.

  本申请公开了一种包含恶臭化合物和抑臭成分的组合物，用于减少恶臭的存在或产生。该组合物可以局部应用于一个对象，并且适用于化妆条件、药用指示或其他目的。
• [EN] INHIBITION OF OXIDATIVE STRESS, GLYCATION, AND PROTEIN CROSSLINKING<br/>[FR] INHIBITION DU STRESS OXYDANT, DE LA GLYCATION ET DE LA RÉTICULATION DE PROTÉINES
  申请人：UNIV COLORADO REGENTS

  公开号：WO2019036336A1

  公开（公告）日：2019-02-21

  Compositions for the treatment and prevention of symptoms and disease conditions associated with oxidative and carbonyl stress, including advanced glycation end products (AGEs), and to methods using the compositions. In particular, the invention relates to compositions useful in the treatment of diabetic retinopathy and nephropathy, to compositions useful in the treatment of other retinal disorders including macular degeneration and cataracts.

  用于治疗和预防与氧化和羰基应激相关的症状和疾病状态的组合物，包括高级糖基化终末产物（AGEs），以及使用这些组合物的方法。特别地，本发明涉及用于治疗糖尿病视网膜病变和肾病的组合物，用于治疗其他视网膜疾病，包括黄斑变性和白内障的组合物。
• Use of stimulators of glutathione synthesis as hait growth promotors
  申请人：Transcend Therapeutics, Inc.

  公开号：EP0656201A1

  公开（公告）日：1995-06-07

  The composition is topically, or otherwise administered, to stimulate intracellular glutathione synthesis. Specifically, the composition may include glutathione esters; L-2-oxothiazolidine-4-carboxylic acid; and esters of 2-oxothiazolidine-4-carboxylic acid.

  该组合物用于局部或以其他方式给药，以刺激细胞内谷胱甘肽的合成。具体来说，组合物可包括谷胱甘肽酯、L-2-氧代噻唑啉-4-羧酸和 2-氧代噻唑啉-4-羧酸酯。
• Glutathione monoester sulfonate
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：EP0806432A1

  公开（公告）日：1997-11-12

  The present invention relates to glutathione monoester sulfonate represented by formula (I): (wherein R1 represents lower alkyl, and R2 represents lower alkyl, or substituted or unsubstituted aryl) which readily crystallizes and has high stability, and a simple process for producing the same. According to the process, the product having high purity can be obtained in high yields.

  本发明涉及由式（I）代表的谷胱甘肽单酯磺酸盐： (其中 R1 代表低级烷基，R2 代表低级烷基或取代或未取代的芳基），该产品易结晶且稳定性高，还涉及一种生产该产品的简单工艺。根据该工艺，可以高产率获得高纯度的产品。